Phaseline

Targets › TCRA

TCRA (T cell receptor alpha chain constant): drug programs, companies and trials

4 programs from 4 companies in 7 trials: 4 Phase 1, 3 Phase 2; Oncology, Hematology, Metabolic and endocrine; next expected readout Jan 2027.

Constant region of T cell receptor (TR) alpha chain. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. (UniProt, P01848)

Open in Phaseline: the race on TCRA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Masonic Cancer Center, University of MinnesotaT cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC)
Selective depletion of T cells expressing TCR alpha/beta to reduce graft-versus-host disea
TCRA, TCRBPhase 2Fanconi AnemiaJan 2027
Johns Hopkins All Children's HospitalTCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
TCR alpha beta T-cell and CD19 B-cell depleted haploidentical hematopoietic cell transplan
TCRA, TCRB, CD19Phase 2Hemoglobinopathy (Disorder); Primary Immune Deficiency DisordersJun 2027
Marengo TherapeuticsSTAR0602
Selective TCR-targeting bifunctional antibody-fusion molecule
TCRA, TCRBPhase 1Triple Negative Locally Advanced Non-resectable Breast Cancer; Advanced Solid TumorsJan 2027
Chinese PLA General HospitalTCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T c
Allogeneic CAR-T cell therapy targeting CD19 with TCR alpha/beta chain (TRAC) and SPPL3 ge
TRBC, SPPL3, CD19, TCRAPhase 1Acute Lymphocytic Leukemia; Non-hodgkin LymphomaFeb 2027

Conditions

Acute Lymphocytic Leukemia (1) Non-hodgkin Lymphoma (1) Hemoglobinopathy (Disorder) (1) Primary Immune Deficiency Disorders (1) Fanconi Anemia (1) Triple Negative Locally Advanced Non-resectable Breast Cancer (1) Advanced Solid Tumors (1)

Modalities

mixed (2), other (1), small molecule (1)

Companies

Chinese PLA General Hospital (1) Johns Hopkins All Children's Hospital (1) Masonic Cancer Center, University of Minnesota (1) Marengo Therapeutics (1)

Related targets

TCRB (3) CD19 (2) TRBC (1) SPPL3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.